Labopharm Reports Results for Third Quarter F...(----------------------------------------...),Health

Date:11/6/2009

------------------------------------------------------------------------- REVENUE Product sales 5,187 3,863 13,816 9,880 Licensing 1,191 5,576 3,664 7,701 Royalties 201 - 325 - Research and development collaboration 46 - 46 - ------------------------------------------------------------------------- 6,625 9,439 17,851 17,581 ------------------------------------------------------------------------- EXPENSES Cost of goods sold (excluding depreciation and amortization) 2,154 1,755 6,151 4,389 Research and development expenses, net 3,209 6,267 10,097 18,264 Selling, general and administrative expenses 7,999 4,963 21,033 16,079 Financial expenses 1,013 733 3,010 2,153 Impairment loss on long-term investment - 400 - 1,091 Depreciation and amortization 442 501 1,358 1,476 Interest income (84) (351) (378) (1,554) Foreign exchange loss (gain) (1,215) 488 (3,679) 196 ------------------------------------------------------------------------- 13,518 14,756 37,592 42,094 ------------------------------------------------------------------------- Loss before income taxes (6,893) (5,317) (19,741) (24,513) Provision for income taxes Current 11 700 11 1,500 ------------------------------------
'/>"/>

SOURCE Labopharm Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine news :

1. Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings
2. Labopharms response for novel trazodone formulation accepted by FDA as complete - Designated as Class 2 resubmission
3. Labopharm submits response to FDA for novel antidepressant
4. Labopharm Reports Results for Second Quarter Fiscal 2009
5. Labopharm to present at Canaccord Adams 29th Annual Global Growth Conference
6. Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)
7. Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
8. Labopharm amends debt facility agreement with Hercules
9. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
10. Labopharm Reports Results for First Quarter Fiscal 2009
11. Labopharm announces details for first quarter results conference call and annual meeting